BR112014012288A2 - métodos para diagnosticar e tratar fibrose pulmonar idiopática - Google Patents

métodos para diagnosticar e tratar fibrose pulmonar idiopática

Info

Publication number
BR112014012288A2
BR112014012288A2 BR112014012288A BR112014012288A BR112014012288A2 BR 112014012288 A2 BR112014012288 A2 BR 112014012288A2 BR 112014012288 A BR112014012288 A BR 112014012288A BR 112014012288 A BR112014012288 A BR 112014012288A BR 112014012288 A2 BR112014012288 A2 BR 112014012288A2
Authority
BR
Brazil
Prior art keywords
methods
pulmonary fibrosis
diagnosing
idiopathic pulmonary
treating idiopathic
Prior art date
Application number
BR112014012288A
Other languages
English (en)
Inventor
Kossen Karl
D Seiwert Scott
Lim Sharlene
Ziegler Bradford Williamson
Qin Xiaoli
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of BR112014012288A2 publication Critical patent/BR112014012288A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Nuclear Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

resumo métodos para diagnosticar e tratar fibrose pulmonar idiopática são descritos aqui materiais e métodos para o diagnóstico de fibrose pulmonar idiopática.
BR112014012288A 2011-11-22 2012-11-21 métodos para diagnosticar e tratar fibrose pulmonar idiopática BR112014012288A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161562770P 2011-11-22 2011-11-22
US201261648548P 2012-05-17 2012-05-17
PCT/US2012/066221 WO2013078283A1 (en) 2011-11-22 2012-11-21 Methods of diagnosing and treating idiopathic pulmonary fibrosis

Publications (1)

Publication Number Publication Date
BR112014012288A2 true BR112014012288A2 (pt) 2017-05-23

Family

ID=47258131

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012288A BR112014012288A2 (pt) 2011-11-22 2012-11-21 métodos para diagnosticar e tratar fibrose pulmonar idiopática

Country Status (11)

Country Link
US (1) US20130150426A1 (pt)
EP (1) EP2783016A1 (pt)
JP (1) JP2015504307A (pt)
CN (1) CN103987858A (pt)
AU (1) AU2012340698A1 (pt)
BR (1) BR112014012288A2 (pt)
CA (1) CA2853136A1 (pt)
EA (1) EA201491019A1 (pt)
HK (2) HK1201298A1 (pt)
MX (1) MX2014006130A (pt)
WO (1) WO2013078283A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986538B1 (fr) * 2012-02-06 2016-03-11 Centre Nat Rech Scient Utilisation du mir-199a-5p de ses cibles et/ou inhibiteurs pour le diagnostic, le pronostic et le traitement des pathologies fibroproliferatives
EP2852669B1 (en) 2012-05-22 2018-07-18 Ruprecht-Karls-Universität Heidelberg Therapeutic micro rna targets in chronic pulmonary diseases
CN104560991B (zh) * 2013-10-10 2021-02-26 复旦大学附属妇产科医院 用于防治人乳头瘤病毒感染和宫颈癌的微小rna
GB201403489D0 (en) * 2014-02-27 2014-04-16 Univ London Queen Mary Biomarkers for endometriosis
US20170226507A1 (en) * 2014-05-05 2017-08-10 The Brigham And Women's Hospital, Inc. Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
CN105132525B (zh) * 2014-05-29 2018-11-09 中国医学科学院基础医学研究所 miRNA分子在精神分裂症的诊断和预后中的用途
EP2957634A1 (en) * 2014-06-20 2015-12-23 Consejo Superior De Investigaciones Científicas Compounds for prevention and/or treatment of fibrotic diseases
US9376681B2 (en) 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
WO2016054094A1 (en) * 2014-09-30 2016-04-07 Research Institute At Nationwide Children's Hospital Compositions and methods for treating hepatic fibrosis
CN105624271A (zh) * 2014-10-28 2016-06-01 广州复能基因有限公司 一种与结直肠癌相关的miRNA及其应用
CN104450707B (zh) * 2014-12-25 2017-08-29 厦门大学 一种血清miRNA生物标志物的应用
CN104694542A (zh) * 2015-03-19 2015-06-10 中国人民解放军第四军医大学 一种促进组织工程骨血管化的 microRNA 及其应用
CN105079808B (zh) * 2015-05-22 2018-04-03 重庆医科大学 miR590的用途及其相关药物
JP2018517418A (ja) * 2015-06-15 2018-07-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 情動障害の診断および治療の方法
GB201513128D0 (en) * 2015-07-24 2015-09-09 Sense Biodetection Ltd Nucleic acid detection method
CN105106972A (zh) * 2015-08-13 2015-12-02 常州市第一人民医院 miR-338-5p及靶向作用于miR-338-5p核酸制剂的新用途
CN105169393B (zh) * 2015-08-31 2018-07-03 北京泱深生物信息技术有限公司 miRNA-548a-3p抗急性髓系白血病中的应用
CN109477144B (zh) 2015-09-29 2022-12-09 国家儿童医院研究所 用于检测肝脏纤维化和对疗法的响应性的方法
JP2017143810A (ja) * 2016-02-19 2017-08-24 学校法人慶應義塾 抗酸菌症又は抗酸菌感染のバイオマーカー
CN106011303B (zh) * 2016-08-08 2019-05-24 南京市妇幼保健院 一种与儿童肥胖相关的血清或血浆miRNA标志物及其应用
WO2018170622A1 (zh) * 2017-03-18 2018-09-27 深圳市博奥康生物科技有限公司 一种同步下调微小rna-152和微小rna-185表达的方法
WO2018170652A1 (zh) * 2017-03-19 2018-09-27 深圳市博奥康生物科技有限公司 多重敲低三种miRNA的Tud RNA及其应用
CN107236799B (zh) * 2017-06-15 2020-06-09 昆明医科大学第六附属医院 一种肾纤维化miRNA标记物
CN108186564B (zh) * 2018-01-03 2020-06-02 上海市肿瘤研究所 一种肿瘤微环境响应型基因纳米胶束及其制备方法和应用
CN108611414A (zh) * 2018-04-26 2018-10-02 北京工业大学 新的靶向肿瘤微环境与肺癌干细胞相互作用的miRNA的检测及应用
CN109486911A (zh) * 2018-11-28 2019-03-19 上海纳米技术及应用国家工程研究中心有限公司 基于滚环扩增和DNA折纸术检测microRNAs的方法
CN109825575A (zh) * 2019-04-08 2019-05-31 首都医科大学附属北京胸科医院 辅助诊断结核病的miRNA标志物及其应用
CN110055322A (zh) * 2019-05-12 2019-07-26 青岛大学 用于急性心肌梗死诊断的循环miRNA标志物及其应用
KR20220035123A (ko) * 2019-06-14 2022-03-21 카디오르 파마슈티컬스 게엠베하 인간 개체의 심부전 치료
EP3999661A1 (en) 2019-07-16 2022-05-25 Université de Liège Extracellular vesicles containing mir-142-3p to treat fibrosing diseases
JP7392224B2 (ja) * 2020-02-19 2023-12-06 国立医薬品食品衛生研究所長 びまん性肺胞傷害型薬剤性間質性肺炎のｍｉＲＮＡ診断バイオマーカー

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5124246A (en) 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5359100A (en) 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5681702A (en) 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6090822A (en) 1995-03-03 2000-07-18 Margolin; Solomon B. Treatment of cytokine growth factor caused disorders
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
US5962478A (en) 1995-09-19 1999-10-05 Margolin; Solomon B. Inhibition of tumor necrosis factor α
US7785842B2 (en) 1996-03-26 2010-08-31 Oncomedx, Inc. Comparative analysis of extracellular RNA species
EP1258484B1 (en) 2000-02-18 2009-01-14 Kyowa Hakko Kirin Co., Ltd. Novel isoxazole and thiazole compounds and use thereof as drugs
US6956044B1 (en) 2000-02-21 2005-10-18 Margolin Solomon B Compositions and methods for treatment of epilepsy
WO2002062389A1 (fr) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedes pour des maladies urinaires contenant des agents de regulation du recepteur de lpa
ATE448784T1 (de) 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
JP2005027804A (ja) 2003-07-10 2005-02-03 Konica Minolta Medical & Graphic Inc 診察支援システム、データ処理端末及びデータ処理プログラム
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
AU2003284808B2 (en) 2003-11-14 2009-01-22 Catalyst Biosciences, Inc. The derivatives of pyridone and the use of them
EP2322650A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
US20060292616A1 (en) 2005-06-23 2006-12-28 U.S. Genomics, Inc. Single molecule miRNA-based disease diagnostic methods
EP2043635A2 (en) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmaceutical combinations
CA2656851C (en) 2006-07-05 2013-12-10 Fibrotech Therapeutics Pty Ltd Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity
CN101842355A (zh) 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20100323357A1 (en) * 2007-11-30 2010-12-23 The Ohio State University Research Foundation MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer
US20110098352A1 (en) 2008-02-01 2011-04-28 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2096171A1 (en) * 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
WO2010039502A2 (en) * 2008-09-23 2010-04-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Micrornas in idiopathic pulmonary fibrosis
WO2010054386A2 (en) * 2008-11-10 2010-05-14 Battelle Memorial Institute Methods, compositions, and devices utilizing microrna to determine physiological conditions
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
AU2010206543A1 (en) 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders
US20120059020A1 (en) * 2009-05-29 2012-03-08 Shizuoka Coffein Co., Ltd Prophylactic or therapeutic agent for pulmonary fibrosis
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
IN2012DN00754A (pt) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy

Also Published As

Publication number Publication date
HK1201299A1 (en) 2015-08-28
HK1201298A1 (en) 2015-08-28
WO2013078283A1 (en) 2013-05-30
MX2014006130A (es) 2015-04-13
EA201491019A1 (ru) 2014-08-29
US20130150426A1 (en) 2013-06-13
CA2853136A1 (en) 2013-05-30
AU2012340698A1 (en) 2014-04-24
JP2015504307A (ja) 2015-02-12
EP2783016A1 (en) 2014-10-01
CN103987858A (zh) 2014-08-13

Similar Documents

Publication Publication Date Title
BR112014012288A2 (pt) métodos para diagnosticar e tratar fibrose pulmonar idiopática
IL256396A (en) Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
CR20150046A (es) Anticuerpos anti-cd79b e inmunoconjugados
BR112014007649A2 (pt) material estruturante, e, método para o tratamento de uma formação subterrânea
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
BR112015030203A2 (pt) moléculas pequenas inibidores da fibrose
DK3292116T3 (da) 3-aryl-4-amido-bicykliske [4,5,0]hydroxamsyrer som hdac-inhibitorer
DK3584255T3 (da) Modificerede aminosyrer omfattende en azidogruppe
BR112015014758A2 (pt) produtos de cuidado oral compreendendo óxido de zinco e trimetilglicina
BR112012029457A2 (pt) aparelho eletrodoméstico, sistema de aparelho eletrodoméstico e método para operar o mesmo
BR112014018592A2 (pt) composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
UY34676A (es) ?cuchillo para tratamiento de madera, métodos para galvanizado y tratamiento de superficies de cuchillo para tratamiento de madera?.
EA201390583A1 (ru) Композиции для улучшения состояния волос и соответствующие способы
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
EA201400447A1 (ru) АНТИТЕЛА К CD1d
FI20116212A (fi) Polypeptidi
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
EA201400937A1 (ru) Способ получения 2-(2,3-диметилфенил)-1-пропаналя
IT1402643B1 (it) Corpo per pedale strumentato e procedimento di produzione dello stesso.
IT1402511B1 (it) Procedimento di tipo migliorato per la pulitura di rulli, pennelli e simili, e dispositivo di pulitura a secco per la realizzazione di questo procedimento
BR112016025080A2 (pt) método de tratamento de fibrose pulmonar idiopática.
BR112013012366A2 (pt) formulação química agrícola, composição química, e, processo para preparar uma formulação química agrícola
IT1404385B1 (it) Metodo per la realizzazione di calzature e calzatura ottenuta con tale metodo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]